209 related articles for article (PubMed ID: 22410174)
1. Malignancies associated with systemic sclerosis.
Szekanecz É; Szamosi S; Horváth Á; Németh Á; Juhász B; Szántó J; Szücs G; Szekanecz Z
Autoimmun Rev; 2012 Oct; 11(12):852-5. PubMed ID: 22410174
[TBL] [Abstract][Full Text] [Related]
2. A cohort study of cancer incidence in systemic sclerosis.
Derk CT; Rasheed M; Artlett CM; Jimenez SA
J Rheumatol; 2006 Jun; 33(6):1113-6. PubMed ID: 16622904
[TBL] [Abstract][Full Text] [Related]
3. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre.
Kang KY; Yim HW; Kim IJ; Yoon JU; Ju JH; Kim HY; Park SH
Scand J Rheumatol; 2009; 38(4):299-303. PubMed ID: 19308805
[TBL] [Abstract][Full Text] [Related]
4. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
5. Determinants of morbidity and mortality of systemic sclerosis in Canada.
Al-Dhaher FF; Pope JE; Ouimet JM
Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan.
Kuo CF; Luo SF; Yu KH; Chou IJ; Tseng WY; Chang HC; Fang YF; Chiou MJ; See LC
Scand J Rheumatol; 2012 Feb; 41(1):44-9. PubMed ID: 22150162
[TBL] [Abstract][Full Text] [Related]
7. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies.
Onishi A; Sugiyama D; Kumagai S; Morinobu A
Arthritis Rheum; 2013 Jul; 65(7):1913-21. PubMed ID: 23576072
[TBL] [Abstract][Full Text] [Related]
8. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
[TBL] [Abstract][Full Text] [Related]
9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
10. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.
Dreyer L; Faurschou M; Mogensen M; Jacobsen S
Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088
[TBL] [Abstract][Full Text] [Related]
11. [The occurrence of malignancies in a Hungarian lupus population].
Tarr T; Szekanecz E; Zeher M; Szegedi G; Kiss E
Orv Hetil; 2006 Nov; 147(46):2229-33. PubMed ID: 17396395
[TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis and malignancy.
Sargin G; Senturk T; Cildag S
Int J Rheum Dis; 2018 May; 21(5):1093-1097. PubMed ID: 29673080
[TBL] [Abstract][Full Text] [Related]
13. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
14. The risk of cancer development in systemic sclerosis: a meta-analysis.
Zhang JQ; Wan YN; Peng WJ; Yan JW; Li BZ; Mei B; Chen B; Yao H; Yang GJ; Tao JH; Wang J
Cancer Epidemiol; 2013 Oct; 37(5):523-7. PubMed ID: 23725641
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers.
Barnes J; Mayes MD
Curr Opin Rheumatol; 2012 Mar; 24(2):165-70. PubMed ID: 22269658
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis and risk of ischaemic stroke: a nationwide cohort study.
Chiang CH; Liu CJ; Huang CC; Chan WL; Huang PH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
Rheumatology (Oxford); 2013 Jan; 52(1):161-5. PubMed ID: 23238980
[TBL] [Abstract][Full Text] [Related]
17. Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group.
Mansour S; Bonner A; Muangchan C; Hudson M; Baron M; Pope JE;
J Rheumatol; 2013 Apr; 40(4):447-54. PubMed ID: 23418377
[TBL] [Abstract][Full Text] [Related]
18. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis.
Szekanecz E; Szamosi S; Gergely L; Keszthelyi P; Szekanecz Z; Szucs G
Clin Rheumatol; 2008 Sep; 27(9):1163-6. PubMed ID: 18500435
[TBL] [Abstract][Full Text] [Related]
19. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies.
Airo' P; Ceribelli A; Cavazzana I; Taraborelli M; Zingarelli S; Franceschini F
J Rheumatol; 2011 Jul; 38(7):1329-34. PubMed ID: 21459934
[TBL] [Abstract][Full Text] [Related]
20. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
